|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.090 USD | +1.95% |
|
+5.03% | +16.11% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 168.4 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 16.33% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 168.4 | 168.4 | 168.4 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 16.33% | 0% | 0% |
| P/E Ratio | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 10.7x | 41.8x | 209x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.6x | -2.6x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.15x | 2.49x | 2.5x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.15x | 2.49x | 2.5x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 9.61x | 56.7x | 682x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.195 | 0.05 | 0.01 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 78.3 | 67.56 | 67.46 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 17.52 | 2.968 | 0.247 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 15.72 | 4.074 | 0.731 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.090 | 2.090 | 2.090 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 31/03/22 | 27/02/23 | 14/03/24 | 17/03/25 | 18/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 10.72x | - | - | - | 168M | |
| 33.15x | 12.05x | 24.81x | 0.6% | 1,010B | |
| 25.74x | 5.93x | 16.13x | 2.22% | 580B | |
| 27.88x | 6.79x | 13.86x | 3.01% | 402B | |
| 17.71x | 4.37x | 10.73x | 3.04% | 330B | |
| 53.11x | 4.94x | 20.09x | 2.81% | 294B | |
| 22.78x | 4.74x | 13.47x | 1.85% | 280B | |
| 21.24x | 5.49x | 13.32x | 2.92% | 281B | |
| 12.7x | 4.76x | 9.73x | 3.95% | 197B | |
| 23.09x | 6.16x | 10.76x | 2.84% | 192B | |
| Average | 24.81x | 6.14x | 14.77x | 2.58% | 356.72B | |
| Weighted average by Cap. | 28.14x | 7.35x | 17.09x | 2.13% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
